A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA

Active, not recruitingOBSERVATIONAL
Enrollment

625

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Breast Cancer
Trial Locations (19)

Unknown

Research Site, Arkhangelsk

Research Site, Barnaul

Research Site, Belgorod

Research Site, Chelyabinsk

Research Site, Grozny

Research Site, Irkutsk

Research Site, Khanty-Mansiysk

Research Site, Krasnodar

Research Site, Krasnoyarsk

Research Site, Moscow

Research Site, Nal'chik

Research Site, Nyzhny Novgorod

Research Site, Ryazan

Research Site, Saint Petersburg

Research Site, Severodvinsk

Research Site, Sochi

Research Site, Ufa

Research Site, Vladivostok

Research Site, Yaroslavl

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY